Literature DB >> 35122875

Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics.

Dallin Lowder1, Kinza Rizwan1, Collin McColl1, Alyssa Paparella1, Michael Ittmann2, Nicholas Mitsiades3, Salma Kaochar4.   

Abstract

The largest US cancer health disparity exists in prostate cancer, with Black men having more than a two-fold increased risk of dying from prostate cancer compared to all other races. This disparity is a result of a complex network of factors including socioeconomic status (SES), environmental exposures, and genetics/biology. Inequity in the US healthcare system has emerged as a major driver of disparity in prostate cancer outcomes and has raised concerns that the actual incidence rates may be higher than current estimates. However, emerging studies argue that equalizing healthcare access will not fully eliminate racial health disparities and highlight the important role of biology. Significant differences have been observed in prostate cancer biology between ancestral groups that may contribute to prostate cancer health disparities. Notably, relative to White men, Black men with prostate cancer exhibit increased androgen receptor signaling, genomic instability, metabolic dysregulation, and inflammatory and cytokine signaling. Immediate actions are needed to increase multi-center, interdisciplinary research to bridge the gap between social and biological determinants of prostate cancer health disparities.
Copyright © 2022. Published by Elsevier B.V.

Entities:  

Keywords:  African American; Androgen; DNA Damage; Inflammation; Outcomes; Social determinants; Tumor microenvironment

Mesh:

Year:  2022        PMID: 35122875     DOI: 10.1016/j.canlet.2022.01.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  1 in total

1.  Racial Disparities in Prostate Cancer Stage at Diagnosis Persist Despite Community Affluence.

Authors:  Barbara Nemesure; Kathleen H Scarbrough; Linda Mermelstein
Journal:  Res Rep Urol       Date:  2022-08-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.